China Resources Boya Bio-pharmaceutical Group (300294.SZ) Earnings Analysis

China Resources Boya Bio-pharmaceutical Group (300294.SZ) next reports earnings on 2026-08-22, consensus EPS 0.39 CNY. Last quarter (2026-04-25) it beat with EPS 0.0599 CNY vs 0.03 CNY est (+99.7%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -150200.00.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 300294.SZ next report earnings?

Next earnings date2026-08-22
Consensus EPS estimate0.39 CNY
Revenue estimate0.32B

300294.SZ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-250.0599 CNY0.03 CNY+99.7%Beat
2026-03-21-0.46 CNY0.34 CNY-235.3%Miss
2025-04-240.28 CNY0.27 CNY+3.7%Beat
2025-03-18-0.03 CNY0.28 CNY-110.7%Miss
2024-10-240.19 CNY0.3 CNY-36.7%Miss
2024-08-230.33 CNY0.26 CNY+26.9%Beat

Beat rate: 3/6 (50%) over reported quarters with consensus data.

300294.SZ valuation and analyst view

Trailing P/E-150200.00
Trailing EPS0.00681 CNY
Price / book1.01
Dividend yield1.48%
Market cap7.63B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is China Resources Boya Bio-pharmaceutical Group (300294.SZ)'s next earnings date?

China Resources Boya Bio-pharmaceutical Group is next scheduled to report on 2026-08-22, with a consensus EPS estimate of 0.39 CNY and revenue estimate of 0.32B.

Did 300294.SZ beat earnings last quarter?

In its 2026-04-25 report, 300294.SZ posted EPS of 0.0599 CNY versus a 0.03 CNY estimate — a beat of 99.7%.

What is 300294.SZ's earnings track record?

Over the last 6 reported quarters with consensus data, 300294.SZ beat estimates 3 times (50%).

What is 300294.SZ's current P/E ratio and EPS?

300294.SZ trades at a trailing P/E of -150200.00 on trailing EPS of 0.006812290723075642 CNY.

What do analysts rate 300294.SZ?

300294.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.